Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TPP, Sprint Bioscience partner to develop human cancer therapeutics
The partnership will focus on developing the small molecule inhibitors as therapeutics to treat cancer in humans. TPP CEO Tom Brown said the agreement will allow the company
The partnership will focus on developing the small molecule inhibitors as therapeutics to treat cancer in humans. TPP CEO Tom Brown said the agreement will allow the company
The Flanders government has awarded the grant through the agency for innovation by science and technology, IWT. Complix CEO Dr Mark Vaeck said the results generated so far
In addition to the centralized administration, the Web-based quality management system provides scalability to meet PPD’s future growth needs. Sparta Systems product management vice president Michael Jovanis said
The extension could trigger up to $41m research payments to Evotec. Evotec chief operating officer Dr Mario Polywka said, "This collaboration is an excellent example of how companies,
The study will evaluate the safety and tolerability of fulvestrant 500mg compared to anastrozole 1mg in 450 postmenopausal patients with hormone receptor-positive advanced breast cancer and those who
The vaccine was manufactured by Chemo-Sero-Therapeutic Research Institute at Kaketsuken. The bulk materials of Kaketsuken’s adsorbed purified pertussis diptheria tetanus combined vaccine (DPT vaccine) and the bulk of
The Conference, which will be held from 8-9 November, will discuss how to avoid risks of patient or material unblinding when defining drug supply specifications of interactive response
Under the agreement, both the companies will be responsible for the development, registration and manufacture of the biosimilar that leverages BioXpress technology. AET BioTech managing director Dr Harm
VAL-083 has received the Chinese State Food and Drug Administration (SFDA) approval as cancer chemotherapy to treat Chronic Myelogenous Leukemia (CML) and lung cancer. The companies are also
The new Leucovorin Calcium for Injection is indicated for rescue after high-dose methotrexate therapy in osteosarcoma, diminish the toxicity and counteract the effects of impaired methotrexate elimination and